A Phase 2 interventional study of MitoQ and Placebo in Stroke and Stroke Recurrence, sponsored by Medical College of Wisconsin. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Medical College of Wisconsin · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Stroke by Medical College of Wisconsin — 7 open to participants now, 8 under way, none of them phase 3. Stroke · Medical College of Wisconsin.
Among the 18 studies in Stroke by Medical College of Wisconsin, this one is the 7th largest by planned enrollment of the 17 interventional ones that give a count, is the only one that started in 2027, is one of 2 in phase 2, and was the 18th registered.
8,268 studies on the registry are indexed under Stroke; 2,062 are open to participants now.
Browse Stroke studies →7 of the 18 studies in Stroke by Medical College of Wisconsin are open now, in 1 country. Recruiting first, the newest first:
Medical College of Wisconsin · Sites in United States
Ages 18+
Medical College of Wisconsin · Sites in United States
Ages 18–85
Medical College of Wisconsin · Sites in United States
Ages 18–85 · Healthy volunteers
Medical College of Wisconsin · Sites in United States
Ages 18–85
Medical College of Wisconsin · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 1,418 Stroke studies recruiting now, 696 (49%) set no upper age limit and 282 (20%) stop at 75 or younger; 77 take children under 18; 196 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is close to the median of 49 across 6,036 interventional studies indexed under Stroke.
Median enrollment 50 across the 17 interventional studies, 0 across the 1 observational. Of the 9 that completed or were terminated, 1 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
Medical College of Wisconsin is the lead sponsor of 550 studies on the registry; 124 are open to participants now.
Of its 75 completed or terminated interventional studies of FDA-regulated products, 57 (76%) have results posted.
1 of the studies in Stroke by Medical College of Wisconsin that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06930638Medical College of WisconsinMitoQ and Ischemic Conditioning To Assess Vascular Health Outcomes | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies in Stroke by Medical College of Wisconsin, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Stroke survivors have compromised vascular function which may contribute to secondary stroke risk, cardiovascular disease, and may limit their exercise tolerance. Preliminary data shows an antioxidant supplement called MitoQ may improve vascular function and muscle activity in individuals post-stroke.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The investigators will be measuring how an over-the-counter antioxidant supplement, called MitoQ, affects how blood flow responds to movement and exercise. Participants will orally ingest MitoQ during a baseline study visit as well as for 4 weeks at home.
Dietary Supplement: MitoQ
The investigators will compare the effects of MitoQ to a group receiving a placebo sugar pill. Participants will be randomized into receiving MitoQ or placebo. Participants will orally ingest the placebo pill during a baseline study visit as well as for 4 weeks at home.
Dietary Supplement: Placebo
MitoQ is an over the counter supplement that increases delivery to the mitochondria. Similar to studies performed in middle age/older adults and individuals with peripheral arterial disease, we will administer 1 single oral dose of 80mg of MitoQ or a placebo pill. We will examine the acute effects at the baseline vascular visit as well as chronically after 4 weeks of MitoQ supplementation at home.
Placebo
Ultrasound Measured Blood Flow during Passive Limb Movement (PLM)
Microvascular response to passive limb movement
Time frame: Change from baseline to after acute MitoQ (1 hour) and chronic MitoQ (4 weeks).
Ultrasound Measured Blood Flow during Active Limb Contraction
Hyperemic Response to Maximal Voluntary Contractions (MVCs)
Time frame: Change from baseline to after acute MitoQ (1 hour) and chronic MitoQ (4 weeks).
Walking Speed
Physical walking function
Time frame: Change from baseline to after acute MitoQ (1 hour) and chronic MitoQ (4 weeks).
Plan to share: Yes — IDP is available upon reasonable request to the PI.
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Dec 2028, 23 months later.
Of 112 non-industry phase 2 interventional studies under Stroke, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's planned 23 months is below that.
Counting every sponsor, half of 132 studies reached it within 40 months; a quarter within 24 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical College of Wisconsin →